Alliance Pharma PLC Application for block admission (7891I)
June 21 2017 - 09:53AM
UK Regulatory
TIDMAPH
RNS Number : 7891I
Alliance Pharma PLC
21 June 2017
For immediate release 21 June 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Application for block admission
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical
company, announces that it has today applied for a block admission
for a further 25,000,000 ordinary shares of 1p each in the Company
("Ordinary Shares") to be admitted to trading on AIM (the "Block
Admission"). The Block Admission will be used to facilitate the
admission of shares to trading following the exercise of options
granted under the following employee share schemes:
-- The Alliance Pharma plc Approved Share Option Plan 2005 (up
to 2,248,922 shares);
-- The Alliance Pharma plc Share Option Plan 2006 (up to
19,461,225 shares); and
-- The Alliance Pharma plc Company Share Option Plan 2015 (up to
3,289,853 shares).
It is expected that the Block Admission will become effective in
the Ordinary Shares on 28 June 2017.
The Company will make six-monthly announcements of the
utilisation of the Block Admission, in line with its obligations
under AIM Rule 29.
New Ordinary Shares issued following option exercises and
admitted to trading under the Block Admission will rank pari passu
in all respects with the existing Ordinary Shares.
At the time of this application, Alliance has 474,307,589
Ordinary Shares in issue.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Andrew Franklin, Chief Financial
Officer
Rob Bellhouse, Company Secretary
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: James
Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has sales in more than 100 countries worldwide via direct
sales, joint ventures and a network of distributors. Alliance has a
strong track record of acquiring the rights to established niche
products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Company continues to explore opportunities to expand its
product portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSFBMJTMBATBMR
(END) Dow Jones Newswires
June 21, 2017 09:53 ET (13:53 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2023 to Mar 2024